smurf1

Smurf1-IN-A01 (A01) is a ubiquitin ligase Smad ubiquitination regulatory factor-1 inhibitor (Kd: 3.664 nM) that enhances BMP-2 responsiveness by preventing Smurf1-mediated Smad1 5 degradation.

Smurf1 ligand 1 serves as a PROTAC target protein ligand (Ligands for Target Protein for PROTACs) and is utilized in synthesis.

Smurf1 inhibitor 1 is a inhibitor that promotes bone formation.

Smurf1-IN-1, a selective E3 ubiquitin protein ligase 1 (SMURF1) inhibitor, exhibits oral activity with an IC50 of 92 nM and demonstrates considerable efficacy in a rat model of pulmonary hypertension [1].

1-ethyl-6-fluoro-4-oxo-7-[4-(3-phenylpropanoyl)piperazin-1-yl]-1,4-dihydroquinoline-3-carboxylic acid is a compound used as a molecular structural unit and is a SMURF1 inhibitor.

HS-152 is a novel reversible inhibitor of smurf1, directly targeting the catalytic activity of smurf hect domains, significantly blocking auto-ubiquitination and the transfer of ubiquitin from hect domain to the substrates to form isopeptide bond

AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg kg day.

Smurf-1 modulator CMP Example 20 (Smurf-1-IN-20) is a potent Smurf-1 modulator.

SMART1 is a CRBN-dependent PROTAC with high specificity that effectively degrades Smurf1. It inhibits tumor growth in xenograft models of colorectal cancer (CRC) with KRAS mutations and blocks the PDK1-Akt signaling pathway in KRAS-mutated colorectal cancer.